|
| 37683134 | Prognostic Factors for Relapse in Patients With Clinical Stage I Testicular Seminoma: A Nationwide, Population-Based Cohort Study. | J Clin Oncol | 2024 |
| 36221864 | WHO 2022 classification of penile and scrotal cancers: updates and evolution. | Histopathology | 2023 |
| 37954076 | Seminoma and dysgerminoma: evidence for alignment of clinical trials and de-escalation of systemic chemotherapy. | Front Oncol | 2023 |
| 37353740 | Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C-ProMeta-1). | BMC Cancer | 2023 |
| 37084466 | Corrigendum to "Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system?": [Modern Pathology 34 (2021) 834-841]. | Mod Pathol | 2023 |
| 37183161 | European Association of Urology Guidelines on Testicular Cancer: 2023 Update. | Eur Urol | 2023 |
| 37041861 | A Validated Algorithm for Register-Based Identification of Patients with Relapse of Clinical Stage I Testicular Cancer. | Clin Epidemiol | 2023 |
| 36592067 | Fumarate hydratase-deficient testicular sex cord-stromal tumour (FH-TSCST): proposal for reclassification of a subset of Leydig cell tumours with distinct molecular and clinicopathologic features. | Histopathology | 2023 |
| 36779238 | Measuring cancer burden in prostatic needle core biopsies: simplified assessments outperform complex measurements in assessing outcome: evidence to assist pathologist efficiency and minimize datasets. | Histopathology | 2023 |
| 36798177 | Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. | Res Sq | 2023 |
| 36727071 | The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer. | Front Oncol | 2023 |
| 36208048 | Low-grade oncocytic tumour of the kidney is characterised by genetic alterations of TSC1, TSC2, MTOR or PIK3CA and consistent GATA3 positivity. | Histopathology | 2023 |
| 36202687 | Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. | Eur Urol | 2023 |
| 33041185 | Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. | Eur J Cancer | 2022 |
| 35472129 | ETS transcription factor ELF3 (ESE-1) is a cell cycle regulator in benign and malignant prostate. | FEBS Open Bio | 2022 |
| 35502823 | An introduction to the WHO 5th edition 2022 classification of testicular tumours. | Histopathology | 2022 |
| 35853783 | The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. | Eur Urol | 2022 |
| 35758185 | WHO Classification of Tumours fifth edition: evolving issues in the classification, diagnosis, and prognostication of prostate cancer. | Histopathology | 2022 |
| 35596618 | WHO 2022 landscape of papillary and chromophobe renal cell carcinoma. | Histopathology | 2022 |
| 35749784 | Decoding germ cell tumours for clinicians. | Curr Opin Urol | 2022 |
| 36632556 | Testicular adrenal rest tumours in an adult patient with congenital adrenal hyperplasia. | BJR Case Rep | 2022 |
| 35965208 | The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. | Eur Urol | 2022 |
| 36059000 | Accumulation of copy number alterations and clinical progression across advanced prostate cancer. | Genome Med | 2022 |
| 36344186 | Testicular Tumors: New Developments in Germ Cell and Sex Cord Stromal Tumors. | Surg Pathol Clin | 2022 |
| 36083240 | Low-grade prostate cancer should still be labelled cancer. | BJU Int | 2022 |
| 35975974 | The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas. | Endocr Relat Cancer | 2022 |
| 35065204 | Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. | Ann Oncol | 2022 |
| 34958681 | Looking forward for 'Histopathology'. | Histopathology | 2022 |
| 35192975 | Surgical management and outcomes for stage 1 malignant ovarian germ cell tumours: A UK multicentre retrospective cohort study. | Eur J Obstet Gynecol Reprod Biol | 2022 |
| 34423592 | Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy. | Cancer Rep (Hoboken) | 2022 |
| 32381397 | Management of Late Relapses After Chemotherapy in Testicular Cancer: Optimal Outcomes with Dose-intense Salvage Chemotherapy and Surgery. | Eur Urol Focus | 2021 |
| 33490068 | The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing. | Front Cell Dev Biol | 2021 |
| 33780691 | Cribriform prostate cancer: Morphologic criteria enabling a diagnosis, based on survey of experts. | Ann Diagn Pathol | 2021 |
| 34522463 | Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. | Am J Cancer Res | 2021 |
| 34831389 | What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables. | Cells | 2021 |
| 34831388 | What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic-Pathologic Correlations. | Cells | 2021 |
| 34385710 | Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. | Nat Genet | 2021 |
| 34830209 | What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment. | Int J Mol Sci | 2021 |
| 34830196 | What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1. | Int J Mol Sci | 2021 |
| 34830179 | What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 4: Experimental Treatments in Pre-Clinical Studies (Cell Lines and Mouse Models). | Int J Mol Sci | 2021 |
| 33999555 | ISUP Consensus Definition of Cribriform Pattern Prostate Cancer. | Am J Surg Pathol | 2021 |
| 33058949 | Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. | Hum Pathol | 2021 |
| 33477882 | The Transcriptomic Landscape of Prostate Cancer Development and Progression: An Integrative Analysis. | Cancers (Basel) | 2021 |
| 33392799 | 2019 Gleason grading recommendations from ISUP and GUPS: broadly concordant but with significant differences. | Virchows Arch | 2021 |
| 33208404 | Pathologists can get it right the first time. | J Clin Pathol | 2021 |
| 33382927 | Head-to-head review: a new format for the journal. | Histopathology | 2021 |
| 33319858 | Pathological predictors of metastatic disease in testicular non-seminomatous germ cell tumors: which tumor-node-metastasis staging system? | Mod Pathol | 2021 |
| 32989229 | The impact of a supranetwork multidisciplinary team (SMDT) on decision-making in testicular cancers: a 10-year overview of the Anglian Germ Cell Cancer Collaborative Group (AGCCCG). | Br J Cancer | 2021 |
| 31580196 | Reply by Authors. | J Urol | 2020 |
| 34337465 | Overexpression of Placental Growth Factor in Stromal Cells from Benign Prostatic Hyperplasia: Another Piece in the Puzzle? | Eur Urol Open Sci | 2020 |